

The leading data platform for neuroscience



Blackfynn has developed the leading platform to manage, analyze, visualize and collaborate around scientific and clinical data – all in one powerful, cloud-based platform built specifically for neuroscience.

Simplified data management.

Blackfynn is the easiest and most effective way to manage and collaborate on your scientific data with your team.

Access your data from everywhere

Blackfynn lets you and your team manage and access data – no matter where you're located.

Fine-tuned security controls

Keep data private, or share it with your team. Datasets allow you to organize and share your data with collaborators.

Integrates with your existing data

Import your existing scientific data directly to Blackfynn using our powerful REST API or directly through our platform UI.

Explore your data.

Go beyond files and discover more about your data with Blackfynn's Knowledge Graph.

Model data to fit your needs

Describe your data with understood and recognized concepts from ontologies and common data elements – or create your own models.

Rapidly explore your data

Visually explore relationships between your data and discover insights without having to write complex queries.

Discover new relationships.

Create explicit relationships between concepts to get a better understanding of your data.

Powerful, interactive viewing

With Blackfynn, you can view and collaborate on your scientific data, including radiology imaging, EEG, genomics, neural, video, pathology, tabular data and more – without downloading a file.

More than just a viewer

Our interactive, web-based viewers allow you to interact with your data. View, navigate, annotate and explore your data from a wide range of file formats. Zoom and pan imaging data, playback an EEG session in real-time, or add annotations to data – in your browser.

Get everyone on the same page.

Accelerate innovation by empowering you and your team with the collaboration tools they need.

Comments and discussions

Add inline comments and participate in discussions by @mentioning team members to facilitate collaboration.

Smart notifications

Invite members of your team to access datasets. Blackfynn will automatically alert them when data is processed so they can easily review new data.

Collaborative annotations

Annotate data the moment it becomes available and discuss annotations at the source.

Advanced data analysis tools.

Blackfynn integrates into your workflow with our powerful set of APIs and data libraries. Retrieve, upload, annotate, and link concepts to your data programmatically – without downloading entire files. Our open-source Python and command line libraries empower you to seamlessly access data stored in the Blackfynn platform for use in your analytic workflows – in the apps and tools you already use.

Scales to fit your needs.

From small labs to large organizations, our cloud-based platform is flexible and scales to meet your demands. We work with you to help determine the optimal solution you need – today and tomorrow. If you ever need more, we're here to help.


Safe and secure.

Blackfynn gives you the tools to safeguard your sensitive data. We use Secure Sockets Layer (SSL) and 128-bit Advanced Encryption Standard (AES) to create a secure tunnel while your data is being transferred. Your data is stored in using 256-bit encryption. Blackfynn complies with HIPAA standards.

What's included?

We're making the Blackfynn platform available to researchers to empower the discovery of new treatments for neurological disease. Every Blackfynn plan starts with:

- 250 GB of data storage
- Unlimited users
- Access to a growing collection of scientific data viewers
- API access
- Non-PHI data only




What makes us different.

New tools and technologies are generating vast quantities of highly complex and diverse data. Electrical recordings, radiology imaging, genomics, pathology, neurochemistry, device and patient clinical data – together – could hold the keys to understanding the basis of neurological disease. Breakthrough discoveries that could lead to novel therapeutics have been hindered by an inability to see, use, collaborate around, analyze and interrogate all data types in combination to find new data patterns.

Data in neuroscience and neurology is among the most complex in all of science. Given Blackfynn's deep domain expertise in neuroscience, we are focused on using our data platform to enable new treatments for neurological diseases like Alzheimer's disease, epilepsy, Parkinson's disease and others that affect more than one billion people worldwide.

Blackfynn is positioned to change the way neurological disease is treated. Our competitive advantage is derived from our early adoption, unique platform features, and our team's deep domain expertise together with a strong track record of building platform companies.

Early adoption – We are rapidly becoming the leading platform for neuroscience data via our partnerships with SPARC, DARPA, NIDA, Childrens' Hospital of Philadelphia, and others under which the Blackfynn platform will be used by hundreds of the leading neuroscience researchers. We expect to expand our leadership position by growing our partner and user base globally.



Unique platform – The Blackfynn platform is the only data platform that:

- is built specifically for neuroscience and neurology, disciplines that are generating and using some of the most complex data in science.
- brings together and enables visualization, annotation, collaboration, and analysis of every important data type in the field, across an unlimited number of data sets.
- is fully interoperable, allowing researchers to use the data regardless of the format in which it was acquired or the database silo in which it resides.

Domain expertise – Our Founders, Leadership Team, Board of Directors and Advisory Boards are worldwide experts in neurology, neuroscience, computer science, engineering and medicine. Our Leadership Team and Board have successfully led and built multiple successful platform companies in biotechnology.

For more information visit www.blackfynn.com.

Leadership Team

Amanda Christini, MD – co-founder and President. UPenn, Maxygen, Valentis

Chris Baglieri – SVP of Engineering. Bristol-Myers Squibb, Partners HealthCare

Joost Wagenaar, PhD – co-founder & VP of Scientific Applications. UPenn

Board of Directors

Simba Gill, PhD – Chairman. Flagship, Evelo, Moksha8, TPG, Maxygen, Valentis

Michael Rabson, PhD, JD – Director. Cytokinetics, Maxygen, Wilson Sonsini

Advisory Board

Brian Litt, MD – co-founder and Professor of Neurology and Biomedical Engineering, U. of Pennsylvania

Zack Ives, PhD – co-founder and Professor, Associate Dean of Computer Science, U. of Pennsylvania

Doug Weber, PhD – U. of Pittsburgh

Mark Bodmer, PhD – CSO & President of R&D, Evelo

Andrew Cole, MD – Mass General Hospital

John Detre, MD – U. of Pennsylvania

Ray Dorsey, MD – U. of Rochester

Jacqueline French, MD – NYU, Director Epilepsy Study Consortium, CSO Epilepsy Foundation

Rob Gaunt, PhD – U. of Pittsburgh

Sean Grady, MD – U. of Pennsylvania

Warren Grill, PhD – Duke University

Tim Harris, PhD – Formerly SVP Precision Medicine, Biogen

Karl Keiburtz, MD – Parkinson's Progression Markers Initiative

Annamaria Vezzani, PhD – Mario Negri Institute

Karen Wilcox, MD – U. of Utah

Greg Worrell, MD, PhD – Mayo Clinic